Primary Disease

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Stallergenes Greer
Stallergenes GreerFrance - Antony
1 program
1
300 IRPhase 31 trial
Active Trials
NCT00803244Completed381Est. Jan 2010
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
liposomal cytarabinePhase 21 trial
Active Trials
NCT01325194Completed143Est. Dec 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Stallergenes Greer300 IR
Amgenliposomal cytarabine

Clinical Trials (2)

Total enrollment: 524 patients across 2 trials

NCT00803244Stallergenes Greer300 IR

Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis

Start: Jan 2009Est. completion: Jan 2010381 patients
Phase 3Completed
NCT01325194Amgenliposomal cytarabine

CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis

Start: Mar 2011Est. completion: Dec 2019143 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space